Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Press Releases
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
press release
November 22, 2021
FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant…
Read moreObseva Announces Appointment of Stephanie Brown to its Board of Directors
press release
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – ObsEva…
Read moreObsEva Announces Third Quarter 2021 Financial Results and Business Update
press release
November 4, 2021
-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis:…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2021
May 28, 2021
ObsEva Annual General Meeting 2020
June 9, 2020
Upcoming Events
Sorry, there are no events available yes.
Stock Information
Latest Press Release
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant…
Read moreInvestor Contact
Media Contact
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Sign up for news
